ZDA
ACAD icon

Zweig-DiMenna Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Zweig-DiMenna Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-225,010
Closed -$4.08M – 229
2013
Q2 		$4.08M Buy
+225,010
New +$3.1M 0.16% 131

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Zweig-DiMenna Associates's ACAD Position: Q3 2013 in Review

Zweig-DiMenna Associates sold out of Acadia Pharmaceuticals (ACAD) in Q3 2013, closing a stake of 225,010 shares — an estimated $4.08M sold.

Zweig-DiMenna Associates first reported a position in ACAD in Q2 2013 and held it in 1 quarter. The position peaked at $4.08M in Q2 2013. 142 funds tracked by Wall St. Rank hold ACAD as of Q3 2013.

  • Zweig-DiMenna Associates reported no remaining Acadia Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 225,010 Acadia Pharmaceuticals shares in Q3 2013, an estimated $4.08M.
  • Zweig-DiMenna Associates first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Acadia Pharmaceuticals position peaked at $4.08M in Q2 2013.
  • 142 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2013.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2013, filed 12 Nov 2013.